BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Sessa A, Cirillo G, Guarino S, Marzuillo P, Miraglia Del Giudice E. Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management. Pediatric Health Med Ther 2019;10:89-97. [PMID: 31692530 DOI: 10.2147/PHMT.S188989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Q, Wang Z, Pang B, Zheng H, Cao Z, Feng C, Ma W, Wei J. Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1014670] [Reference Citation Analysis]
2 Marcinkiewicz K, Horodnicka-józwa A, Jackowski T, Strączek K, Biczysko-mokosa A, Walczak M, Petriczko E. Nonalcoholic fatty liver disease in children with obesity– observations from one clinical centre in the Western Pomerania region. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.992264] [Reference Citation Analysis]
3 Chijiokwu EA, Nwangwa EK, Oyovwi MO, Naiho AO, Emojevwe V, Ohwin EP, Ehiwarior PA, Ojugbeli ET, Nwabuoku US, Oghenetega OB, Ogheneyoma OO. Intermittent fasting and exercise therapy abates STZ-induced diabetotoxicity in rats through modulation of adipocytokines hormone, oxidative glucose metabolic, and glycolytic pathway. Physiol Rep 2022;10:e15279. [PMID: 36305681 DOI: 10.14814/phy2.15279] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Cuda SE, Kharofa R, Williams DR, O'hara V, Conroy R, Karjoo S, Paisley J, Censani M, Browne NT. Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: An Obesity Medical Association (OMA) Clinical Practice Statement 2022. Obesity Pillars 2022;3:100031. [DOI: 10.1016/j.obpill.2022.100031] [Reference Citation Analysis]
5 Calcaterra V, Magenes VC, Vandoni M, Berardo C, Marin L, Bianchi A, Cordaro E, Silvestro GS, Silvestri D, Carnevale Pellino V, Cereda C, Zuccotti G. Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity. Children 2022;9:1174. [DOI: 10.3390/children9081174] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ma R, Zhan Y, Zhang Y, Wu L, Wang X, Guo M. Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice. Drug Dev Res 2021. [PMID: 34927282 DOI: 10.1002/ddr.21905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Karhan AN, Hizarcioglu-Gulsen H, Gumus E, Akçören Z, Demir H, Saltik-Temizel İN, Orhan D, Özen H. Distinctive Features of Hepatic Steatosis in Children: Is It Primary or Secondary to Inborn Errors of Metabolism? Pediatr Gastroenterol Hepatol Nutr 2021;24:518-27. [PMID: 34796096 DOI: 10.5223/pghn.2021.24.6.518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tursun S, Gülerman HF, Gazyağcı S, Şahin Y, Erel Ö, Neşelioğlu S. Investigation of Thiol/Disulfide Balance in Obese Rats with Non-Alcoholic Fatty Liver Disease. Pediatr Gastroenterol Hepatol Nutr 2021;24:443-54. [PMID: 34557397 DOI: 10.5223/pghn.2021.24.5.443] [Reference Citation Analysis]
9 Al-Baiaty FDR, Ismail A, Abdul Latiff Z, Muhammad Nawawi KN, Raja Ali RA, Mokhtar NM. Possible Hepatoprotective Effect of Tocotrienol-Rich Fraction Vitamin E in Non-alcoholic Fatty Liver Disease in Obese Children and Adolescents. Front Pediatr 2021;9:667247. [PMID: 34307250 DOI: 10.3389/fped.2021.667247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Jiménez-Cortegana C, García-Galey A, Tami M, Del Pino P, Carmona I, López S, Alba G, Sánchez-Margalet V. Role of Leptin in Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:762. [PMID: 34209386 DOI: 10.3390/biomedicines9070762] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
11 Notarnicola M, Osella AR, Caruso MG, Pesole PL, Lippolis A, Tutino V, Bonfiglio C, De Nunzio V, Scavo MP, Mirizzi A, Franco I, Lippolis T, D'Alessandro R, Refolo MG, Messa C. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. Int J Mol Sci 2021;22:3899. [PMID: 33918878 DOI: 10.3390/ijms22083899] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Di Sessa A, Guarino S, Umano GR, Arenella M, Alfiero S, Quaranta G, Miraglia Del Giudice E, Marzuillo P. MAFLD in Obese Children: A Challenging Definition. Children (Basel) 2021;8:247. [PMID: 33806784 DOI: 10.3390/children8030247] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
13 Sindhu S, Leung YH, Arefanian H, Madiraju SRM, Al-Mulla F, Ahmad R, Prentki M. Neutral sphingomyelinase-2 and cardiometabolic diseases. Obes Rev 2021;22:e13248. [PMID: 33738905 DOI: 10.1111/obr.13248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Aneja A, Lal SB. Nonalcoholic Fatty Liver Disease in Children: Spectrum and Consequences. Journal of Postgraduate Medicine, Education and Research 2021;55:39-52. [DOI: 10.5005/jp-journals-10028-1429] [Reference Citation Analysis]
15 Fontana L, Plaza-Díaz J, Robles-Bolívar P, Valente-Godínez H, Sáez-Lara MJ, Abadía-Molina F, Gómez-Llorented C, Gil Á, Álvarez-Mercado AI. Bifidobacterium breve CNCM I-4035, Lactobacillus paracasei CNCM I-4034 and Lactobacillus rhamnosus CNCM I-4036 Modulate Macrophage Gene Expression and Ameliorate Damage Markers in the Liver of Zucker-Lepr fa/fa Rats. Nutrients 2021;13:202. [PMID: 33440736 DOI: 10.3390/nu13010202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
16 Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, Zhang R, Zhao Q, Liu J. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis. Front Immunol 2020;11:1169. [PMID: 32670278 DOI: 10.3389/fimmu.2020.01169] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 15.0] [Reference Citation Analysis]